Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma

Share :
Published: 1 Jul 2022
Views: 57
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain

Dr Anna Sureda speaks to ecancer about, ZUMA-7, a phase 3 randomised clinical trial. This study aimed to compare axicabtagene ciloleucel with standard of care in patients aged 65+ with relapsed/refractory large B-cell lymphoma.

The results showed axicabtagene ciloleucel provides significantly superior event free survival vs standard of care in elderly patients with relapsed/refractory large B-cell lymphoma.  

Dr Sureda explains axicabtagene ciloleucel has now been approved by FDA and could potentially be used as a treatment strategy in the near future.